Higuchi T, Chen X, Siegmund SC, Klimek K, Gröner D, Rowe SP, Fischereder M, Werner RA.

Semin Nucl Med. 2025 Oct 15: S0001-2998(25)00124-2. doi: 10.1053/j.semnuclmed.2025.09.008. Online ahead of print. PMID: 41102069.

Abstract

Recent years have seen substantial advancements in renal positron emission tomography (PET) imaging. Targets for PET imaging include, but are not limited to, angiotensin receptors, norepinephrine transporters, and sodium-glucose cotransporters. All of those novel radiotracers inherit advantages of F18 radiochemistry, thereby allowing for higher clinical throughput or potentially increased diagnostic accuracy. The potential of such novel F18-labeled agents to yield imaging biomarkers, and their potential role for future renal molecular imaging, will be presented in the following article.